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Strategies of gene transfer to the kidney. Kidney targeted gene transfer
has been a realistic goal for many researchers since 1991, but unfortu-
nately, to date there is no reliable gene transfer technique for gene therapy
of renal diseases. However, at the experimental level, several in vivo gene
transfer methods have attempted to target certain renal structures, for
example, the HVJ-liposome method and renal perfusion of adenovirus for
glomerular cells, intravenous injection of oligonucleotides (ODNs) for
proximal tubule, intra-arterial injection of adenovirus followed by cold
incubation with a vasodilator for interstitial vasculature of the outer
medulla, and adenoviral injection into the renal pelvis for the inner
medullary collecting duct. As an ex vivo gene transfer method targeting the
glomerulus, the transfusion of genetically-modified mesangial cells has
been attempted. Implantation of genetically-modified tubular epithelial
cells into the subcapsular region has been employed for ex vivo transfec-
tion to the interstitium. Gene therapy has focused particularly on the
transplanted kidney, where an exogenous gene can transferred in advance.
In the future, an inducible system and individual cell targeting strategy
should be developed. The improvement of gene transfer techniques,
especially vectors for delivering genes, is crucial. The potential application
of gene transfer technologies is enormous while the therapeutic ap-
proaches have just begun to be explored. Therapeutic interventions of the
process of progression of glomerulonephritis in the rat have been directed
towards inhibiting the actions of growth factors. Obviously, molecular
biological intervention is coming of age and there is a tremendous
excitement over its potential. We believe that gene transfer techniques will
become common tools for the dissection of molecular aspects of diseases
and possibly for gene therapy in the field of nephrology.
The first gene therapy in human beings was done in a girl with
adenosine deaminase (ADA) deficiency in 1990 [1]. This therapy
succeeded in the long-term expression of the transferred ADA
gene in T lymphocytes, and the girl who suffered from severe
immunodeficiency was allowed to return to school. This happy
story was a tantalizing step forward in the application of basic
research to clinical problems, and since then general interest
concerning gene therapy has exploded. From the first clinical trial
seven years ago, more than 200 protocols for human gene therapy
have been approved and 2100 patients were recruited for gene
therapy by the end of 1996 [2]. Gene therapy was originally a
clinical strategy in which genetic material is transferred to somatic
cells to correct an inherited genetic disorder. The rationale of
somatic gene therapy is the correction of the cause(s) of diseases
at the most fundamental level. The application of gene therapy
has been extended to the treatment of acquired diseases including
cancer, human immunodefficiency virus (HIV) infection and
vascular diseases. To date, two thirds of the diseases addressed by
gene therapy have been malignancies while only 10% have been
congenital deficiencies [2].
Potentially, gene therapy may provide: (1) a correction of
cellular dysfunction by expressing the deficient gene, (2) the
addition of a new function for a cell by transferring an exogenous
gene and (3) inhibition of unfavorable action of a cell by
introducing a counteracting gene. The most attractive aspect of
gene therapy is the introduction of a functional molecule into a
cell, because transferring a protein across the plasma membrane
of a targeted cell is rather difficult compared to transferring DNA.
While clinical trials examining human gene therapy are apparently
increasing at a remarkable rate, significant information regarding
the long-term efficacy and adverse consequences are still generally
lacking. One cutting report on gene therapy was released by Orkin
and Motulsk from the National Institutes of Health (Bethesda,
MD, USA) in 1995 [3]. They pointed out important issues on gene
therapy, and in particular, the weakness of the basic research on
gene therapy. They believed that more attention should be paid to
comprehension of disease pathophysiology, to extend the knowl-
edge of which cells should be targeted and which gene(s) should
be corrected for the physician to accomplish the most effective
therapy. The development of gene transfer techniques, especially
vector(s) for delivering a gene, is crucial for the improvement of
gene transfer efficacy. As nephrologists, we should accept these
criticisms about gene therapy calmly and make every effort to
promote fundamental research. Although the technologies for
gene therapy are not fully developed, the logic of gene therapy
continues to be compelling. Recent reviews have summarized the
progress of human gene therapy [4–9], and others have focused
on its application to renal diseases [10–14].
In contrast to somatic cell gene manipulation, germ line gene
manipulation is ethically prohibited for human gene therapy.
Germ line mutation has been used for producing new phenotypes
of animals. The mutation can be established by nonhomologous or
homologous recombinations. The former is used as a strategy to
produce transgenic mice and the latter is for null mutated mice,
the so-called “knock out” mice.
In this review, recent progress on somatic cell gene transfer
techniques and their application to nephrology are discussed.
STRATEGIES FOR GENE TRANSFER
Strategies of gene transfer techniques are classified into two
categories: viral vector and non-viral vector methods. For human
gene therapy, 75% of clinical trials thus far have been performed
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with viral vectors. Generally viral vectors afford a good transfec-
tion efficiency compared with the non-viral method.
Viral vectors
Retrovirus. Retroviruses have been employed in more than 50%
of clinical trials [2] because the basic biology of the retrovirus has
been extensively studied [6]. This virus binds to a specific receptor
of the cells and transfers the viral RNA genome into the cyto-
plasm. Reverse transcription of the RNA yields proviral DNA,
and the proviral DNA is transported to the nucleus where it is
converted to a double stranded DNA and randomly integrated
into the host genome. The stable incorporation of the expression
cassette into the genome is advantageous for the potential long-
term expression of the transgene. The major disadvantage of the
retrovirus vector is the prerequisite that target cells must replicate
to integrate into the host genome. Since many target cells in the
kidney are non-dividing and terminally differentiated, retroviral
vector-based gene transfer systems have restricted their use
almost entirely to ex vivo applications in human gene therapy. To
overcome this problem, a psudotype vector has been developed
[15]. A retrovirus system was developed using two viral pheno-
types [16]: HIV and vesicular stomatitis virus (VSV). Three
plasmids were constructed for the system. The recombinant HIV
was utilized for the expression cassette of the exogenous gene and
the packaging construct. The plasmid coding cDNA for the G
glycoprotein of vesicular stomatitis virus (VSVG) provided the
envelope protein. The HIV based vector can transduce genes
efficiently into non-proliferative cells in vivo. A potential risk of
using the retrovirus is carcinogenesis. Random integration could
potentially cause insertional mutagenesis by activation of onco-
genes and disruption of tumor suppresser genes.
Adenovirus vectors. Recombinant adenoviruses have been used
for gene delivery vectors. Native adenovirus is a double stranded
DNA virus whose gene expression is controlled by four early
regions and five late regions in the virus genome. The recombi-
nant adenoviral vectors are deleted from the first early region
(E1), which codes most of the functional proteins, including the
transactivator protein of this virus. Thus, the recombinant adeno-
virus theoretically does not replicate by itself. The adenoviral
vector has distinct advantages of high titers and is expected to
show the highest level of expression of the transgene among the
available vectors. The adenovirus vector has a significant advan-
tage in delivering relatively large genes (up to 10 kb) into
quiescent or terminally differentiated cells, since this virus can
infect both dividing and non-dividing cells. However, the expres-
sion of the transfected gene is limited to weeks or months because
the adenovirus does not integrate into the host cell genome. A
crucial obstacle of adenoviral gene transfer is to elicit the appro-
priate immunological responses. The host response consists of an
initial nonspecific inflammation followed by specific cellular and
humoral immune responses directed at the cytotoxic T-lympho-
cyte (CTL)-mediated clearance of the recipient cells [17]. There-
fore, the adenovirus vector cannot be employed for repeated gene
transfer. In attempting to create a harmless adenoviral vector, a
second generation adenovirus was produced that inhibited the
transactivation of the major late regions by insertion of a temper-
ature sensitive mutation into the E2 region [18]. Thereby, the
second generation adenovirus showed prolonged expression of
the transgene according to a reduced cytotoxic T-lymphocyte
response. Third generation adenovirus vectors have been con-
structed to reduce the immunogenicity of the virus by further
deletion of the E2a and E4 regions [19, 20]. These new vectors are
expected to improve the toxicity profile and prolong the transgene
expression by reducing the CTL-mediated elimination of trans-
fected cells. However, this modification may result in the reduc-
tion of the titer of the modified adenoviral vector. Dematteo et al
[21] reported another strategy to avoid the potent immune
response to adenoviral vectors. They inoculated a recombinant
adenovirus in the thymus of neonatal mice. When the virus was
administrated intravenously to these mice in adulthood, they
observed an impaired response of T cells against the adenovirus.
The transfected adenovirus continuously expressed the trans-
ferred gene for up to 260 days.
Adeno-associated virus. Recombinant adeno-associated virus
(AAV) have emerged as attractive alternatives to retroviral
vectors. The AAV, a parvovirus, is a single stranded DNA virus
that has the ability to integrate site-specifically on human chro-
mosome 19 [4]. This virus can infect both non-dividing cells and
dividing cells. However, a recent study demonstrated that the
recombinant AAV does not always integrate on the chromosome
19 [22]. Despite that study, the generation of a recombinant virus
is generally intricate and results in low viral titers. Baudard et al
[23] reported a new method that uses the liposome as a vehicle for
in vivo delivery of AAV vectors. The human multidrug resistance
protein was successfully expressed in the spleen, liver and kidney
by a single intravenous administration of a liposome-AAV com-
plex. Kessler et al [24] demonstrated an attractive application of
the AAV vector for gene therapy targeted to skeletal muscle. The
sustained expression of the transgene for 32 weeks and the
systemic delivery of biologically significant levels of a therapeutic
protein for up to 40 weeks were observed after a single intramus-
cular administration of the AAV virus. Similar observations were
reported on the long-term expression of the transgene by skeletal
muscle-targeted AAV gene transfer [25].
Non-viral vectors
Liposome-mediated gene transfer. There are two concepts of
liposome-mediated gene delivery [26]: the electrostatic type and
the internal type. The electrostatic type of liposome, which was
originally developed by Felgner et al [27], is made by the
attachment of small cationic liposomes to negatively charged
DNA. Cationic lipids are capable of forming positively charged
liposomes that have been applied to in vitro gene delivery for more
than 10 years because of their convenience and efficacy [28]. The
composition of synthetic lipid is N-[1-(2,3-dioleyloxy]propyl]-
N,N,N-trimethylammonium chloride (DOTMA). This electro-
static DNA-liposome complex is taken up into the cell mainly by
phagocytosis. In contrast, the internal type of cationic liposome
contains genetic materials inside the lipid bilayer. Theoretically,
the liposome has no limitation on the size of the packaged genetic
materials. The weakness of liposome-mediated gene transfer is
that the expression efficiency is considerably lower than those
obtained with viral vectors. Recently, the improvement of the
transfection efficiency was reported by using a new cationic lipid
in the formulation of liposomes. Goyal and Huang [29] developed
the new cationic liposome containing 3b[N-(N9-N9-dimethylami-
noethane)-carbamoyl]cholesterol (DC)-cholesterol, which is the
only material that has been approved for use in human gene
therapy. Wheeler et al [30] developed a new cationic liposome
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composed of N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecy-
loxy)-1-propaniminium bromide/dioleoyl phosphatidylethano-
lamine (GAP-DLRIE/DOPE). Lee et al also produced a new
formulation [31]. These new cationic liposomes allowed signifi-
cant improvement of the efficacy of in vivo gene transfer (1000- to
100,000-fold increase in expression). Another disadvantage of the
present liposome-mediated gene transfer system is that it cannot
target specific cells.
HVJ-liposome. The fusogenic character of HVJ, which belongs
to the paramyxovirus family and has HN and F glycoproteins on
its envelope, has been applied to HVJ-liposome-mediated gene
transfer [32]. The HN and F glycoproteins cooperate to achieve a
fusion of the virus and cell [33]. Whereas the HN protein binds to
a receptor, sialic acid, and degrades the receptor as a consequence
of its own neuraminidase activity, the F glycoprotein is cleaved to
generate a hydrophobic fusion peptide by various proteases. The
activated F glycoprotein can fuse with almost all of the cells except
the peripheral lymphocytes. Native viral RNA and protein are
introduced into the cytosol of the fused cell. The HVJ-liposome is
classified as an internal type of liposome, and the HVJ-liposome
method relies on this characteristic in combination with liposomes
consisting of a lipid bilayer that can be used to encapsulate
particular genetic material and proteins. The high mobility group
(HMG)-1, a non-histone nuclear protein, undergoes nuclear
translocation. Co-introduction of HMG-1 with DNA accelerates
gene expression by several mechanisms including the facilitation
of the translocation of the DNA into the nucleus [33].
The HVJ-liposome method possesses several advantages. (1)
The HVJ-liposome method can effectively transfer DNA into
undividing cells. (2) DNA is processed less by the endosome and
lysosome systems in that DNA can be directly introduced into the
cytoplasm and rapidly translocated to the nucleus by the HVJ-
liposome method. (3) The HVJ-liposome method requires a
relatively short incubation time (5 to 30 min). (4) The HVJ-
liposome is capable of transferring double-stranded DNA at sizes
up to 50 kb. (5) The HVJ-liposome transfection system has no
apparent cytotoxic effects in small animals. (6) Repeated admin-
istration of the HVJ-liposome does not significantly affect the
transfection efficiency, although the antibody against HVJ is
produced. (7) Transfer of oligodeoxynucleotides (ODNs) has the
particular advantage of long-term retention and stability of DNA
in the nucleus by an unknown mechanism. The limitations of the
HVJ-liposome method are as follows: (1) The gene expression is
transient. (2) Targeting the delivery of the gene is impossible. (3)
Preparation of the vector for the HVJ-liposome DNA complexes
is complicated and the vector is less stable than in other methods.
New liposome method. Liposome can deliver genetic materials
to a specific cell by conjugating with antibody or ligands. For
example, liposomes combined with an antibody against a mouse
major histocompatibility antigen could deliver DNA more effi-
ciently to the target cells than the liposome-DNA complex alone
[34]. The endothelial cells activated by IL-1b express E-selectin.
Spragg et al achieved endothelial-selective delivery of DNA by
conjugation of liposome with a monoclonal antibody against the
extracellular domain of E-selectin [35]. The liposomes conjugated
with the antibody bound selectively to activated endothelial cells.
Fender et al recently reported a new device using a dodecahe-
dron, that is, an adenoviral protein responsible for cell attach-
ment, internalization and liberation of the virus into the cytoplasm
[36]. They used the dodecahedron as a component of artificial
cationic liposome system to improve the transfection efficiency.
This idea may lead to a super-liposome containing specific
adhesion proteins on its surface so that DNA can be delivered to
the individual cells expressing the acceptor.
GENE TRANSFER INTO THE KIDNEY
The targeted gene transfer into the kidney has been a challenge
since 1991 [37]. Strategies of gene transfer into the kidney are
summarized in Table 1.
Targeting the glomerulus
The glomerulus is a focal point of the inflammatory response in
the initiation and development of various glomerular diseases.
Thus, the technique of gene transfer into glomeruli is attractive
for understanding the mechanisms of glomerular diseases and
may also be applied as a therapeutic approach to glomerular
diseases.
In vivo gene transfer. There are at least two methods available
for the in vivo gene transfer into the glomeruli: the HVJ-liposome
method and a perfusion system of the adenoviral gene transfer.
HVJ-liposome mediated gene transfer allows selective gene de-
livery to the glomeruli, mainly the mesangial cells [38, 39].
Fluorescein isothiocyanate (FITC)-labeled oligonucleotides
(ODNs) were observed in almost all the glomeruli within 20
minutes after transfection, suggesting the susceptibility of HVJ-
liposome mediated gene transfer to mesangial cells [38]. However,
the mechanism of the selective delivery to mesangial cells is not
well understood. Even with the high efficiency of the gene
transfer, the expression of the gene was restricted to 15 to 35% of
the glomeruli [40–42]. The intraglomerular expression of the
transfected gene is limited to, at most, seven days. The critical
issues of HVJ-liposome gene transfer are thus the low transfec-
tion efficiency and the short duration of the expression.
Generally, intra-arterial injection of adenovirus by itself, even
with incubation by clamping the renal vessels, does not lead to
successful gene transfer into kidney. Tryggavason and colleagues
[43, 44] demonstrated for the first time the successful gene
transfer into the glomerulus by means of the adenovirus vector.
They tried to introduce the adenovirus vector by means of the
kidney perfusion system, and perfusion of the adenovirus was
performed for two hours. Four days later transgene expression
was observed in 75% of the glomeruli and the expression lasted
for three weeks. The expression of the transgene, b-galactosidase,
was observed mainly in podocytes, while expression of b-galacto-
sidase was weaker in endothelial cells and mesangial cells. Inter-
estingly, they did not observe any expression of the transgene in
parietal epithelial cells and tubular cells. The adenovirus perfu-
sion system allows selective gene transfer targeting the glomerulus
with high efficacy.
Ex vivo gene transfer. Two strategies have been reported on
glomerular targeted ex vivo gene transfer: infusion of genetically-
modified mesangial cells into the renal artery and transplantation
of a kidney with an already transferred gene. This approach can
avoid the contamination of the transfection accessories such as
viral proteins or chemicals. Extensive work concerning ex vivo
gene transfer using the mesangial cell vector system has been
done by Kitamura et al [45, 46]. The established mesangial cell
line continuously expressing the transfected foreign gene was
injected into the renal artery. Mesangial cells were trapped in the
capillaries of the glomeruli and the expression of the exogenous
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gene was observed in the glomeruli for four weeks. This mesangial
cell vector system provided a strong and long-term expression of
the transfected genes in vivo. However, the transplanted mesan-
gial cells did not migrate into the original mesangial area, but
remained in the endocapillary lumen.
A kidney for transplantation could be a good target for gene
transfer. Heikkla et al perfused isolated pig kidneys with a
solution containing adenovirus. The perfusion of the adenovirus
vector through the renal artery for 12 hours resulted in intense
expression of the reporter gene in 85% of the glomeruli [43].
Targeting the tubule
The tubule is composed of more than ten different cells that
play various roles in concert to maintain fluid and electrolyte
homeostasis. Recent progress in molecular nephrology has re-
vealed nephron heterogeneity based on the presence of functional
components in each nephron segment, for example, various
channels, transporters, enzymes, etc. Therefore, the correction of
the nephron dysfunction should be accomplished by correction of
a particular molecule in the individual nephron segment. How-
ever, there are no specific tubular cell-targeted gene transfer
techniques. Obstacles regarding gene transfer in tubular cells
include: (1) for an approach from the renal artery, genetic
materials must pass through the glomerular basement membrane;
and (2) selective delivery to the proximal segments is difficult
using a retrograde approach.
The simplest transfer into the proximal tubule is the intrave-
nous administration of genetic material. The intravenously in-
jected oligonucleotides (ODNs) accumulate in the proximal tu-
bule by phagocytosis. Rappaport et al [47] studied the fate of
32P-labeled ODNs after intravenous injection. The labeled ODNs
were predominantly localized in kidney and liver and were
detected in the proximal tubular cells within 30 minutes after
injection. Oberbauer, Schreiner and Meyer [48] also reported that
intravenously injected ODNs gathered in proximal tubules, and
electron microscopic observations showed that ODNs did not
merely accumulate in the brush border or lysosomal compartment
in proximal tubular cells, implying that they were not totally
degenerated after being phagocytosed by the proximal tubule.
Oberbauer et al [49] applied this characteristic of the ODNs that
were taken up by the proximal tubular cells to inhibit a sodium/
phosphate cotransporter (Na/Pi-2). A single injection of the
antisense ODNs against the Na/Pi-2 cotransporter inhibited both
mRNA and the protein for the Na/Pi cotransporter, and conse-
quently suppressed phosphate uptake into the brush border
membrane vesicles of the proximal tubule. These results suggest
that the renal proximal tubule is a good target for antisense
therapy.
Lien and Lan [50] reported that the DOTMA:DOPE-DNA
complex can be successfully transferred into the tubular cells by
intra-renal artery injection as well as by renal pelvic injection in
mice. They observed the expression of the reporter gene in the
tubule mainly in the outer medulla for six weeks after intra-renal
pelvic injection. However, the expression of the inner medulla is
weak and has no expression in the glomeruli or vascular or
interstitial components. Intrarenal arterial injection of a
DOTMA:DOPE/DNA complex successfully expressed the re-
porter gene in the tubular cells in the outer medulla and cortex
two to three weeks after injection. However, no positive expres-
sion was observed in the glomeruli and expression of the trans-
gene was not seen after intrarenal parenchymal injection. They
applied this transfection to gene therapy for the carbonic anhy-
drase II deficient mouse [50]. In consequence of this study, in the
mouse transfected with a carbonic anhydrase II gene there was a
partial correction of the renal tubular acidosis.
The direct retroviral gene transfer to the proximal tubule was
Table 1. Strategies for gene transfer into the kidney
In vivo gene transfer into the kidney
Species Targeted region/cell Vector Access
Duration of
expression Reference
rat glomerulus HVJ-liposome/plasmid renal artery 7 days [40, 41, 42]
pig glomerulus adenovirus renal perfusion (2 hr) 3 weeks [43]
rat proximal tubule native ODNs peripheral vein ND [47, 48]
rat proximal tubule DOTMA;DOPE/native ODNs peripheral vein ND [66]
rat proximal tubule DOTMA:DOPE/plasmid renal artery 3 weeks [50]
rat proximal tubule adenovirus renal artery 1–2 weeks [52]
rat proximal tubule retrovirus renal artery after folate injury 3 weeks [51]
rat interstitium outer medulla adenovirus renal artery cold/vasodilater 4–8 weeks [53]
rat outer medulla DOTMA:DOPE/plasmid renal pelvis 6 week [50]
rat IMCD adenovirus renal pelvis 1–2 weeks [52]
ex vivo gene transfer to the kidney
Species Targeted region/cell Vector cell Access
Duration of
expression Reference
rat glomerulus mesangial cell renal arterial 4–8 weeks [45]
rat glomerulus macrophage renal arterial ND [89]
mouse interstitium subcapsular proximal tubule cell renal subcapsular 4 weeks [56]
rat glomerulus/tubule metanephros renal subcapsular 3 weeks [37]
pig glomerulus adenovirus renal perfusion (12 h) 2–3 weeks [43]
human proximal tubule adenovirus/polylysine-Ab perfusion ND [54]
ND is not determined.
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reported by Bosch, Woolf and Fine [51]. Rats were pretreated
with cytotoxic reagent folic acid to induce proliferation of the
proximal tubule, and then retrovirus vector was injected into the
renal artery. In consequence, a weak expression of the reporter
gene was detected in the proximal tubule.
Recently, three different reports concerning in vivo adenoviral
gene transfer to the kidney have been published. Moullier et al
[52] observed very weak and patchy expression of the reporter
gene in the cortex when the adenovirus were simply injected into
the renal artery. The expression lasted for two weeks. The
retrograde transfection from the renal pelvis caused intense
expression of the reporter gene in the papilla and medulla. The
expression lasted for one to two weeks. In contrast, Heikkila et al
demonstrated that no tubular expression was observed by perfus-
ing the kidney with the adenovirus [43]. In addition, Zhu et al
reported no significant transfection of adenovirus to the tubular
cells, but that there was transfection to the interstitial vasculature,
as discussed below [53]. The reasons for these different outcomes
despite using similar adenoviral vectors needs to be clarified.
Zeigler et al reported the first trial of ex vivo gene transfer into
the isolated human kidney under the conditions of organ preser-
vation [54]. They used an adenovirus polylysine DNA complex
and pulsatile perfusion for two hours at 4°C. The gene delivery
and expression were localized to a significant fraction in the
proximal tubular epithelial cells.
Targeting the interstitium
Zhu et al reported on a successful adenoviral vector transfec-
tion into the interstitial compartment [53]. Their method for gene
transfer to the kidney is cold incubation and use of vasodilators.
They injected an adenovirus vector solution containing papaver-
ine into the renal artery of a cold kidney packed with frozen
phosphate buffer saline, and both renal artery and vein clamped
for 45 minutes. The prominent expression of the reporter gene of
b-galactosidese was observed in the interstitial vasculature includ-
ing arterial blood vessels in outer medulla in both the outer and
inner stripes and in periglomerular and peritubular capillaries in
cortex, but not in tubular epithelial cells. They also challenged the
cold preservation technique for gene transfer to a rat model of
polycystic kidney disease (Han:SPRD rat). Adenovirus was in-
fused into the renal pelvis followed by a 30 to 60 minute
incubation. The b-galactosidase activity was seen in cortical
interstitial tissues including interstitial cells and epithelial cells of
the cyst in the Han:SPRD rat.
As an ex vivo approach, the implantation of genetically-modi-
fied tubular epithelial cells (TEC) into the subcapsular region has
been reported [55, 56]. The transplanted TEC remained under the
renal capsule and the transferred gene maintained its expression
for at least four weeks. The authors applied this modified TEC as
a vehicle to deliver a selected cytokine to examine whether a
specific molecule causes the tubulointerstitial injury.
STRATEGIES OF GENE THERAPY FOR EXPERIMENTAL
RENAL DISEASES
Antisense therapy
The ability of short, single stranded ODNs to interdict individ-
ual gene expression in a sequence specific manner is the basis for
antisense therapy [57–60]. Antisense ODNs, which are designed
to bind to complementary mRNA, can inhibit the gene expression
by cleavage of the target mRNA with RNaseH and/or by attenu-
ation of translation. Antisense ODNs, usually 15 to 25 nucleic acid
bases long, are designed to use a unique sequence relative to the
entire genome and to avoid simple repeated or palindrome
sequence. The translation initiation site is often used for antisense
design. The other sequence from the 39 non-coding region,
however, may confer the strongest inhibitory effect [61]. Anti-
sense ODNs are modified by phosphorothioate linkage to stabilize
the ODNs against nucleases. Although the antisense effect is
based on the Watson-Crick base pairment formation, one should
be cautious with the effect of non-antisense ODNs. Therefore, it
is essential to demonstrate that the antisense effect is comparable
with the reduction of the targeted mRNA as well as the protein
level. Burgess et al [62] reported that four consecutive guanosine
residues inhibit cell proliferation in vitro. A sequence independent
induction of transcription factor Sp1 by phosphorothioate ODNs
was also reported [63]. There are two reports concerning the
antisense effect on the progression of glomerulonephritis. Both of
them used the internal type of liposomes to target the glomeruli.
Akagi et al [38] demonstrated that anti-TGF-b antisense ODNs
inhibited the TGF-b expression in Thy1 glomerulonephritis using
the HVJ-liposome method. They transferred the ODNs selec-
tively to glomeruli two days after injection of anti-Thy1 antigen.
Glomerular ECM accumulation was significantly suppressed in
nephritic rats in parallel with the reduction of TGF-b expression
in the glomeruli. Kashihara, Maeshima and Makino [64] reported
a similar effect on the suppression of ECM accumulation using
antisense ODNs for TGF-b. They also demonstrated that treat-
ment with platelet-derived growth factor-B (PDGF-B) antisense
ODNs suppressed hypercellularity in the glomeruli of Thy1
glomerulonephritis. Alternatively, proximal tubule targeted anti-
sense therapy was reported. Intravenous injection of antisense
ODNs resulted in their accumulation in the proximal tubule and
inhibited individual gene expression. Noiri et al [65] applied
antisense ODNs against inducible nitric oxide (NO) synthase in
the inhibition of inducible nitric oxide synthase (iNOS) in an
ischemic kidney. A single intravenous injection of iNOS antisense
ODNs attenuated acute renal failure and improved the morpho-
logical changes. Haller et al [66] reported attenuation of ishemic-
reperfusion injury by administration of antisense ODNs against
ICAM-1. They transferred ODNs with DOTMA:DOPE six hours
prior to 30 minutes of bilateral artery clamping. The ICAM-1
expression was significantly suppressed by antisense treatment.
Consequently, the cortical renal damage and leukocyte infiltration
was attenuated in association with preservation of renal function.
Antisense ODNs are potentially applicable for the intervention of
various renal diseases, although the short-term effects and tar-
geted delivery give reasons for concern.
Transcription factor decoy
A novel gene therapy strategy using a transcription factor decoy
has been reported by Morishita et al [67]. Double stranded ODNs
containing a cis-element for a particular transcription factor act as
a “decoy.” The transfection of an excess decoy using an internal
type liposome results in the attenuation of the authentic cis-trans
interaction of the gene promoter leading to the dissociation of the
transcription factor from the endogenous cis-element. Conse-
quently, the particular gene expression is inhibited. Decoy strat-
egy has some advantages over antisense strategy: (1) double
stranded DNA is more stable, (2) a single decoy can suppress
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multiple genes coding of the same cis-element in the promoter
region, and (3) a decoy can inhibit the constitutively expressing
factor. Two reports have come out on the inhibitory effects of the
progression of Thy-1 glomerulonephritis. Both the E2F decoy [68]
and the NFkB decoy [64] successfully inhibited the mesangial cell
proliferation and ECM expansion in experimental glomerulone-
phritis. The disadvantage of decoy strategy is its inability to
selectively inhibit single gene expression. The genes coding a
targeted cis-element in promoter region may eventually be sup-
pressed by the decoy ODNs.
Muscle targeted gene therapy
Systemic delivery of the therapeutic protein made by the
transferred gene is an alternative method of gene therapy [69].
Skeletal muscle is the target of gene therapy because the muscle
is easily transfected, there is an abundance of capacity and it is
highly vascularized. After gene transfer, the transgene is able to
produce secreted protein constantly for two to three weeks [70,
71]. Producing an expression vector system is less expensive and
overcomes the need to highly purify a recombinant protein. The
long-term expression of the transgene and stable delivery of the
produced protein by means of skeletal muscle gene transfer may
provide a practical strategy for the treatment of inherited and
acquired protein deficiencies. Isaka et al applied decorin gene
therapy to the treatment of experimental glomerulonephritis [72].
The proteoglycan decorin is a natural inhibitor of transforming
growth factor beta (TGF-b). They transferred a plasmid vector
expressing decorin into rat skeletal muscle by the HVJ-liposome
method, and confirmed the increase in production of decorin in
the skeletal muscle and the accumulation in the kidney. The
glomerular extracellular matrix (ECM) accumulation and protein-
uria were significantly suppressed in transfected nephritic rats in
comparison with the reduction of TGF-b mRNA and its protein.
This result suggests that manipulation of TGF-b gene expression
in the process of glomerular injury may ameliorate the progres-
sion of glomerulonephritis. To this end, Isaka et al also con-
structed artificial soluble TGF-b type II receptors that are com-
posed of the extracellular domain of the TGF-b type II receptor
and IgG Fc [72]. The chimeric soluble receptor inhibits both
TGF-b actions on cell proliferation and ECM metabolism in
cultured cells. In addition, the chimeric protein that was system-
atically supplied from the expression vector significantly inhibited
ECM accumulation in the glomeruli of animals with experimental
glomerulonephritis.
The adenovirus was also used for skeletal muscle gene transfer
[73, 74]. The adeno-associated virus (AAV) vector was reported
to express the transgene in skeletal muscle and to last the systemic
delivery. Kessler et al reported that after a single intramuscular
administration of an AAV vector containing a gene for human
erythropoietin, it was expressed in the muscle for 40 weeks [24]. In
consequence, the serum level of erythropoietin reached 700
mU/ml and the hematocrit was sustained over 80%. Gene therapy
transferring AAV vectors into the skeletal muscle may be feasible
to provide systemic supplementation of the individual protein for
the treatment of inherited and acquired protein deficiencies.
Mesangial cell vector system
As mentioned above, the mesangial vector system is a sophis-
ticated approach to examine the action of a specific molecule in
glomeruli. Kitamura et al established mesangial cell line express-
ing TGF-b continuously and injected to the renal artery to deliver
the TGF-b expressing mesangial cells to the glomerulus [75]. In
consequence, [3H] thymidine incorporation into glomerular cells
was suppressed, suggesting that TGF-b produced by exogenous
mesangial cells inhibits the [3H] thymidine incorporation into
glomerular cells. Furthermore, they observed a similar inhibition
of the suppression of mitogenic response in nephritic glomeruli
induced by anti-mesangial cell antibody. However, it is possible
that the long-term existence of exogenous mesangial cells may
elicit the immunological reaction.
FUTURE PERSPECTIVES
Control of the expression of transfected genes
If the transferred gene is continuously expressed after a suc-
cessful intervention of the disease, there must be a mechanism for
switching it off. An ideal gene transfer system should possess the
regulator since the transfected gene may overproduce the coding
product in some situations. For this purpose, several approaches
have been reported using inducible eukaryotic promoter systems
responding to heat shock, heavy metals, steroid hormones, cyto-
kines and aromatic hydrocarbones. These systems are unfulfilled
as a functional molecular switch, since they are a less sensitive
on/off system. Gossen and Bujard developed a sophisticated
regulatory system using a tetracycline-regulated transactivation
system [76]. This method is based on the regulatory element of the
tetracycline resistance operon of E. coli, in which the transcription
of resistance-mediating gene is negatively regulated by the tetra-
cycline repressor (tetR). In the presence of tetracycline, tetR does
not bind to its operators located within the promoter region of the
operon. In this system, a tetracycline-controlled hybrid transacti-
vator (tTA; a fusion protein between the tetracycline repressor of
the E. coli-derived operon and the activating domain of the herpes
simplex virus protein, VP16) can induce the transactivation of the
exogenous promoter containing the tetracycline operetor se-
quences in the absence of the tetracycline. Tetracycline inhibits
this tTA-dependent transactivation by binding to tTA. Kitamura
applied this system to the mesangial cell vector system [77].
Mesangial cells were co-transfected with a regulatory plasmid
coding tTA and a response plasmid coding LacZ driven by
promoter containing tetracycline operator sequences. The estab-
lished mesangial cells were transplanted in the glomeruli via the
renal artery. When tetracycline was withdrawn the expression of
b-galactosidase was observed in three days, and in turn, oral
administration of tetracycline completely suppressed the expres-
sion of b-galactosidase in three days. The tetracycline regulatory
system is strict, reversible and site-specific control over transgene
expression in the glomerulus. This regulatory system provided a
suitable control system for adjusting the delivery of therapeutic
proteins for more than 20 weeks in mice transplanted with
engineered primary myoblasts [78]. No, Yao and Evans reported
an insect steroid hormone, the ecdysone regulatory system [79].
They produced two lines of transgenic mice, one carrying a
modified ecdysone receptor gene together with retinoid X recep-
tor (RXR) gene and the other carrying an ecdysone-responsive
promoter ligated to a reporter gene. They obtained a hybrid
mouse carrying both genes, as shown by bleeding, and observed
the ecdysone induction of the reporter gene. In consequence, they
reported that this system provides a lower level of basal activity
and has higher inducibility (induction reaching 10,000-fold higher
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in magnitude) compared with the tetracycline system. Delort and
Capecchi [80] also reported a similar system using a synthetic
steroid receptor (TAXI), which binds antiprogestins, such as
mifepristone (RU486) and an inducible promoter (UAS) contain-
ing an RU486 responsive element.
Cre recombinase has been used for the control of the activa-
tion/inactivation of the transgene in the genome [81]. Cre binds to
a 34 nt loxP site and mediates the excisional deletion of a DNA
sequence flanked by a pair of loxP sites. The gene activation can
be achieved by the excisional deletion of the stuffer DNA that lies
between the promoter and coding region. In turn, the strategy of
the gene inactivation can be completed by deletion of the
enhancer element from the promoter region. The Cre-LoxP
system is applied to the transgenic mouse carrying two LoxP sites
in targeting the promoter, which turns the molecular switch on by
the infection of the adenovirus vector coding Cre gene [82–84].
The obstacle to this Cre-LoxP system is that the molecular switch
causes irreversible changes in the transgene.
Transcriptionally targeted gene therapy
It is important to restrict the expression of the transferred gene
to the individual cells. Cell-specific or tissue-specific gene expres-
sion is regulated by a cis-acting control sequence and trans-acting
factor. Kidney specific promoter may be useful if the gene delivery
system cannot target to the renal cell. The expression vector
cassette driven by the viral promoter and kidney specific enhancer
may select the gene expression in the renal cells. Miller and
Whelan reviewed tissue specific genes and their specificities [85].
To use the cis-element in the particular promoter of expression
vector may allow the cell specific expression in vivo. The phos-
phoenolpyruvate carboxykinase gene [86], the Na-K-2Cl trans-
porter gene [87] and aquaporin 2 gene [88] are reported to show
nephron segment-selective gene expression. However, the cellular
sequence is sometimes overridden by the strong viral transcrip-
tional controls in the viral based expression cassette.
Tissue and cell engineering
Transplanted kidneys have become a new target of gene
therapy. The gene transfer technique may apply as an interven-
tional strategy to inhibit mediators of the immunologic response
in rejection of the transplanted kidney. As mentioned above,
Zeigler et al aimed to reduce the rejection of a transplanted
kidney by using the immunosuppression of an isolated organ [54].
Another method is ex vivo gene transfer to renal cells or hema-
topoietic cells. Kitamura et al have developed the mesangial cell
vector system [45] and macrophage vector [89]. Cells that were
genetically modified and given a specific function in vitro were
injected into the renal artery to be delivered to the glomerulus.
This method may be potentially applicable as a novel therapy to
provide the immunosuppressive proteins and antifibrotic mole-
cules at the inflammatory glomerulus in situ [90]. The transplan-
tation of the tissues containing genetically modified myoblasts in
silicone rubber molds is a new strategy for gene therapy [91].
Subcutaneous organoid implantation allows systemic delivery of a
bioactive compound and subsequent surgical removal leads to its
rapid disappearance. Hume has proposed a concept of the tissue
engineering of a bioartificial kidney that will be synthesized with
genetically modified cells and hollow fibers [92].
CONCLUSION
We still have no satisfactory and reliable gene transfer tech-
nique for the kidney. A more effective and selective gene transfer
technique needs to be developed for human gene therapy as well
as for research to understand the pathophysiology of renal
diseases. The ambition of understanding the molecular mecha-
nisms of the kidney in physiological and pathological conditions,
and enthusiasm to correct the cause of diseases at the fundamen-
tal level must become strong driving forces to develop new
technologies to overcome the current obstacles in gene transfer.
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Abbreviations used in this article are: ODNs, oligonucleotides; ADA,
adenosine deaminase; VSV, vesicular stomatitis virus; VSVG, G glyco-
protein of the VSV; HIV, human immunodefficiency virus; E1, early
region in the virus genome; CTL, cytotoxic T-lymphocyte; AAV, adeno-
associated virus; DOTMA, N-[1-(2,3-dioleyloxy]propyl]-N,N,N-trimethyl-
ammonium chloride; DC-cholesterol, new cationic liposome containing
3b[N-(N9-N9-dimethylaminoethane)-carbamoyl]cholesterol; GAP-DL-
RIE/DOPE, N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-pro-
paniminium bromide/dioleoyl phosphatidylethanolamine; TGF-b, trans-
forming growth factor-beta; ECM, extracellular matrix; PDGF-B, platelet-
derived growth factor-B; NO, nitric oxide; iNOS, inducible nitric oxide
synthase.
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